Oculis Holding AG (OCS) EBITDA (2022 - 2026)
Oculis Holding AG's EBITDA came in at $617,437 for Q2 2026, up 36.7% from $451,751 a year earlier and up 33.2% from the prior quarter.
Powered by 
Analysis
Oculis Holding AG (OCS) EBITDA (2022 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Oculis Holding AG reported EBITDA of $2.29 million, up 59.0% year-over-year; for FY2025, it came in at $2.18 million, up 75.9% from FY2024.
- EBITDA carries a five-year compound annual growth rate of 13.3% (FY2020 to FY2025).
- Going back by year, EBITDA was $1.24 million in FY2024 (-5.9%), $1.32 million in FY2023 (+3.9%), $1.27 million in FY2022 (+10.7%) and $1.15 million in FY2021 (-2.0%).
- The five-year range for quarterly EBITDA is $142,690 (Q4 2024) to $711,916 (Q4 2025).
- Year-over-year, EBITDA has increased for six consecutive quarters, with growth averaging 61.0% over the last eight quarters.
- The fastest year-over-year change in EBITDA over five years came in Q4 2025 (growth of 398.9%), and the weakest in Q4 2024 (a decline of 51.1%).
- Business Quant data shows OCS's EBITDA at $463,553 (Q1 2026), $711,916 (Q4 2025) and $493,793 (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 9.10 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 8.33 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 999.00 Mn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 5.09 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 4.63 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -9.70 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 5.89 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 1.30 Bn |
| 10 | Oculis Holding AG | 473.32 Mn | 473.32 Mn | - | 617,436.68 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 617,436.68 |
| Mar 31, 2026 | 463,552.70 |
| Dec 31, 2025 | 711,915.61 |
| Sep 30, 2025 | 493,793.26 |
| Jun 30, 2025 | 451,750.95 |
| Mar 31, 2025 | 453,798.22 |
| Dec 31, 2024 | 142,690.23 |
| Sep 30, 2024 | 390,122.05 |
| Jun 30, 2024 | 369,335.02 |
| Mar 31, 2024 | 337,976.28 |
| Dec 31, 2023 | 291,984.81 |
| Sep 30, 2023 | 330,588.55 |
| Jun 30, 2023 | 394,822.32 |
| Mar 31, 2023 | 285,426.92 |
| Dec 31, 2022 | 429,741.07 |
| Sep 30, 2022 | 226,765.00 |
API Access
Oculis Holding AG EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda&ticker=OCS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda", "ticker": "OCS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda&ticker=OCS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();